Iranian Journal of Basic Medical Sciences

Iranian Journal of Basic Medical Sciences

Allele-specific disruption of KRAS p.G12V in colorectal cancer cells using electroporated Cas9 RNPs

Document Type : Original Article

Authors
Firouzeh Morshedzadeh 1
Samaneh Sharif 2, 3
Maryam Peymani 1
Malihe Lotfi 2
Mohammad Reza Abbaszadegan 2, 3
1 Department of Genetics, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran
2 Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
10.22038/ijbms.2026.94681.20422
Abstract
Objective(s): Colorectal cancer (CRC) is a major cause of mortality, and KRAS mutations drive tumorigenesis and therapy resistance. Although CRISPR-Cas9 enables precise genome editing, intracellular delivery of Cas9 ribonucleoproteins (RNPs) remains challenging. We evaluated direct electroporation of Cas9-sgRNA RNPs targeting KRAS p.G12V in SW480 CRC cells to assess delivery efficiency, on-target editing, off-target activity, and viability effects.
Materials and Methods: An sgRNA targeting KRAS p.G12V was designed computationally. Cas9-sgRNA RNPs were assembled and validated by in vitro digestion. RNPs were electroporated into SW480 cells using a square-wave electroporation protocol; pmaxGFP served as the delivery control. On-target editing and five predicted off-target loci were assessed by Sanger sequencing and TIDE analysis. Cell viability was measured by the MTT assay.
Results: Electroporation resulted in high GFP expression (~97%). TIDE analysis at the KRAS locus estimated ~27% total indels. Cells treated with KRAS-targeting RNPs exhibited significantly reduced viability compared with controls (P<0.05). No detectable indels were observed at the five off-target sites. While supporting feasibility, deeper sequencing and mechanistic analyses are needed to confirm specificity.
Conclusion: Direct electroporation of Cas9-sgRNA RNPs enabled efficient intracellular delivery and targeted disruption in SW480 cells, reducing viability without detectable editing at selected off-target loci. This approach is practical for KRAS-targeted studies in CRC and warrants further investigation. Direct electroporation of Cas9–sgRNA RNPs enabled efficient delivery in SW480 cells, accompanied by reduced viability, with no detectable editing at selected off-target candidates by Sanger/TIDE. These findings support RNP electroporation as a practical approach for KRAS-targeted studies in CRC and justify follow-up with amplicon deep sequencing and additional cell models.
Keywords
Allele-specific
Colorectal cancer
CRISPR
Electroporation
KRAS
Ribonucleoprotein complex
Subjects
1. Houseini ST, Nemati F, Sattari A, Azadeh M, BishehKolaei R. Design of crRNA to regulate microRNAs related to metastasis in colorectal cancer using CRISPR-C2c2 (Cas13a) technique. Cell J 2023; 25:354-362.
2. Meng H, Nan M, Li Y, Ding Y, Yin Y, Zhang M. Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer. Front Endocrinol 2023; 14: 1148412.
3. Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 2021; 20:143.
4. Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer. Cancer Metastasis Rev 2020; 39:1029-1038.
5. Meng M, Zhong K, Jiang T, Liu Z, Kwan HY, Su T. The current understanding on the impact of KRAS on colorectal cancer. Biomed Pharmacother 2021; 140:111717.
6. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science 2014; 346:1258096.
7. Hille F, Richter H, Wong SP, Bratovič M, Ressel S, Charpentier E. The biology of CRISPR-Cas: Backward and forward. Cell 2018; 172:1239-1259.
8. Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, et al. Evolution and classification of the CRISPR–Cas systems. Nat Rev Microbiol 2011; 9:467-477.
9. Ju E, Li T, Ramos da Silva S, Gao S-J. Gold nanocluster-mediated efficient delivery of Cas9 protein through pH-induced assembly-disassembly for inactivation of virus oncogenes. ACS Appl Mater Interfaces 2019; 11:34717-34724.
10. Wiesinger M, März J, Kummer M, Schuler G, Dörrie J, Schuler-Thurner B, et al. Clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-Specific CAR under full GMP compliance. Cancers 2019; 11:1198.
11. Nouri M, Sharif S, Soltani E, Mozaffari-Jovin S, Abbaszadegan MR. Performance of KRAS mutation detection in plasma exosomes from patients with early-stage colorectal cancer. J Transl Med 2025; 23:730. 
12. Mirzaei F, Eslahi A, Karimi S, Alizadeh F, Salmaninejad A, Rezaei M, et al. Generation of zebrafish models of human retinitis pigmentosa diseases using CRISPR/Cas9-mediated gene editing system. Mol Biotechnol 2024; 66:2909-2919.
13. Li C, Psatha N, Gil S, Wang H, Papayannopoulou T, Lieber A. HDAd5/35++ adenovirus vector expressing anti-CRISPR peptides decreases CRISPR/Cas9 toxicity in human hematopoietic stem cells. Mol Ther Methods Clin Dev 2018; 9:390-401.
14. Cattaneo C, Enzo E, De Rosa L, Sercia L, Consiglio F, Forcato M, et al. Allele-specific CRISPR-Cas9 editing of dominant epidermolysis bullosa simplex in human epidermal stem cells. Mol Ther 2024; 32:372-383.
15. Brinkman EK, Kousholt AN, Harmsen T, Leemans C, Chen T, Jonkers J, et al. Easy quantification of template-directed CRISPR/Cas9 editing. Nucleic Acids Res 2018; 46:e58-e58.
16. Ryu J-Y, Choi YJ, Won E-J, Hui E, Kim H-S, Cho Y-S, et al. Gene editing particle system as a therapeutic approach for drug-resistant colorectal cancer. Nano Res 2020; 13:1576-1585.
17. Hu Y, Liu L, Jiang Q, Fang W, Chen Y, Hong Y, et al. CRISPR/Cas9: A powerful tool in colorectal cancer research. J Exp Clin Cancer Res 2023; 42:308.
18. Álvarez-Pérez JC, Sanjuán-Hidalgo J, Arenas AM, Hernández-Navas I, Benitez‑Cantos MS, Andrades A, et al. High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models. Nat Commun 2025; 16:7080.
19. Tompkins J, Ray RM, Scott TA. Toward an age of CRISPR delivery with non-viral biologics. Mol Ther Nucleic Acids 2026; 37.
20. Budagyan K, Cannon AC, Chatoff A, Benton D, Kurimchak AM, Araiza-Olivera D, et al. KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation. Cell Rep 2025; 44:115444
21. Javaid N, Choi S. CRISPR/Cas system and factors affecting its precision and efficiency. Front Cell Dev Biol 2021; 9:761709.
22. Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 2014;24:1012-1019. 
23.  Liang X, Potter J, Kumar Sh, Zou Y, Quintanilla R, Sridharan M, et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol 2015:208:44-53.
24. Assa G, Kalter N, Rosenberg M, Beck A, Markovich O, Gontmakher T, et al. Quantifying allele-specific CRISPR editing activity with CRISPECTOR2. 0. Nucleic Acids Res 2024; 52:e78-e78.
25. Karp H, Zoltek M, Wasko K, Vazquez AL, Brim J, Ngo W, et al. Packaged delivery of CRISPR–Cas9 ribonucleoproteins accelerates genome editing. Nucleic Acids Res 2025; 53:gkaf105.
 
Iranian Journal of Basic Medical Sciences
Volume 29, Issue 8
August 2026
Pages 1278-1285